Dr. Vorobiof on Financial Toxicity in Oncology

Video

Daniel A. Vorobiof, MD, discusses financial toxicity in oncology.

Daniel A. Vorobiof, MD, chief medical director of Belong.Life, discusses financial toxicity in oncology.

Financial toxicity is an ongoing problem in the oncology space that has not been properly addressed to date, Vorobiof says.

In the United States, cancer is among the most expensive diseases to treat, along with heart disease, Vorobiof says. Moreover, financial toxicity is a global problem and cancer-related treatment expenses are continuing to rise.

Although financial toxicity may affect all patients differently, some health care professionals have been detached from the widespread burden financial toxicity can place on a patient with cancer, concludes Vorobiof.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine